Cargando…

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen deprivation therapy (ADT). Second-generation antiandrogens have a role in castration-resistant prostate cancer. Nevertheless, some patients do not respond to this therapy, and eventually all the patients became re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinto, Francesco, Dibitetto, Francesco, Ragonese, Mauro, Bassi, Pierfrancesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149952/ https://www.ncbi.nlm.nih.gov/pubmed/35645241 http://dx.doi.org/10.3390/medsci10020025

Ejemplares similares

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer
por: Nowakowska, Malgorzata K., et al.
Publicado: (2021)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Immediate ileal ureter replacement for ureteral avulsion during ureterescopy
por: Ragonese, Mauro, et al.
Publicado: (2020)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Role of prostate cancer stem-like cells in the development of antiandrogen resistance
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
por: Elsesy, Mohamed E., et al.
Publicado: (2020)

Urolithiasis during COVID-19 outbreak: how the pandemic impact hospitalization, complications and clinical management of the patients admitted to emergency department for stone disease
por: Ragonese, M., et al.
Publicado: (2020)

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
por: Zhang, Zeda, et al.
Publicado: (2020)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
por: Kim, Isaac E., et al.
Publicado: (2021)

MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
por: Ottman, Richard, et al.
Publicado: (2014)

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
por: Lee, Eugine, et al.
Publicado: (2019)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

The impact of COVID-19 outbreak on urolithiasis emergency department admissions, hospitalizations and clinical management in central Italy: a multicentric analysis()
por: Antonucci, Michele, et al.
Publicado: (2020)

Designer antiandrogens join the race against drug resistance
por: Josan, Jatinder S, et al.
Publicado: (2013)

Reversing resistance to antiandrogens with a histone deacetylase inhibitor
por: Ferrari, Anna C.
Publicado: (2018)

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants – In vivo evidence
por: Özten-Kandaş, Nur, et al.
Publicado: (2011)

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
por: Flaig, Thomas W., et al.
Publicado: (2017)

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
por: Shah, Neel, et al.
Publicado: (2017)

High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
por: Huhtaniemi, Riikka, et al.
Publicado: (2022)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairment
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Overcoming mutation-based resistance to antiandrogens with rational drug design
por: Balbas, Minna D, et al.
Publicado: (2013)

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
por: Yekedüz, Emre, et al.
Publicado: (2021)

Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers
por: Soundararajan, Rama, et al.
Publicado: (2018)

Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens()()
por: Nunes, Jessica J., et al.
Publicado: (2017)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment
por: Ivachtchenko, Alexandre V., et al.
Publicado: (2014)

Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells
por: Brooke, Greg N., et al.
Publicado: (2015)

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism
por: Gheorghe, Andrei Cristian Dan, et al.
Publicado: (2020)

Advantage of soybean isoflavone as antiandrogen on acne vulgaris
por: Riyanto, Puguh, et al.
Publicado: (2015)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fo6ota3f67bl8mq606sskgaooo